Tadalafil + Placebo + Alpha1 Blocker
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Benign Prostatic Hyperplasia
Conditions
Benign Prostatic Hyperplasia
Trial Timeline
Apr 1, 2015 โ Feb 1, 2016
NCT ID
NCT02431754About Tadalafil + Placebo + Alpha1 Blocker
Tadalafil + Placebo + Alpha1 Blocker is a approved stage product being developed by Eli Lilly for Benign Prostatic Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT02431754. Target conditions include Benign Prostatic Hyperplasia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02431754 | Approved | Completed |
Competing Products
20 competing products in Benign Prostatic Hyperplasia